Recent Stories
American Biotech — The Future Can’t Be Won Without It.RSI is AI Building AI. What DC needs to know about it. Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: Robots

The Wave

Senatein sessionHousein session
Refreshed just now
Hill

FDA has opened a comment period on its draft guidance PSG_218436 covering remibrutinib, with comments due January 20, 2027.

Why it’s here: This is an FDA draft guidance comment deadline on a novel therapeutic (remibrutinib), which falls under Biotechnology's FDA regulation of novel therapies and is a federal regulatory action open for public comment.

Trace across the board

Item

Connected

20 links

About

  • Food and Drug Administration

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy